After total revenue declined 2% in the year, AstraZeneca positioned for product sales growth from FY 2018

AstraZeneca’s revenues improved over the course of the year, Pascal Soriot, Chief Executive Officer, commenting on the results said on Friday in published year results. Its total revenue declined by 2% in the year, in line with guidance.

According to the drugmaker’s CEO, that’s a sign of how AStraZeneca is steadily turning a corner.

“Strong commercial execution helped us bring our science to more patients, making the most of our exciting pipeline,” Soriot said. He added that the company is making “encouraging progress” across the main therapy areas and delivered strong growth in China.

Furthermore, Soriot noted that ,alongside its CVMD medicines Brilinta and Farxiga reaching blockbuster status, AstraZeneca has launched its first Respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence. As well as bringing five new medicines to patients last year, the company said it has been able to find more potential uses for existing cancer treatments like Lynparza and Tagrisso.

“We remain committed to our progressive dividend policy. Our strategy is working, propelled by a strong pipeline, good sales performance and continued cost discipline,” Soriot said.

Image: FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. To match Insight CHINA-CANCER/BLACK MARKET REUTERS/Stefan Wermuth/File Photo